Literature DB >> 22930630

Management of thyroid cancers.

Devendra A Chaukar1, Anuja D Deshmukh, Mitali R Dandekar.   

Abstract

Thyroid cancers cover a large spectrum of disease with diametrically opposite prognosis. At one end of the spectrum we have the well differentiated cancers which carry an excellent prognosis, while at the other end there is anaplastic cancer with high mortality rates and dismal prognosis. Management of thyroid cancers still has some controversial issues due to lack of randomized controlled trials. Extent of surgery, extent of neck dissection, role of radioiodine treatment and thyroid stimulating hormone suppression are still debatable. In this review, we highlight these controversial issues and give guidelines for the management and follow up of patients with thyroid cancer.

Entities:  

Keywords:  Radioiodine treatment; Thyroglobulin; Thyroid cancer

Year:  2010        PMID: 22930630      PMCID: PMC3421010          DOI: 10.1007/s13193-010-0029-3

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  77 in total

1.  Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?

Authors:  Chao Ma; Jiawei Xie; Anren Kuang
Journal:  J Nucl Med       Date:  2005-07       Impact factor: 10.057

2.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group.

Authors:  D P Byar; S B Green; P Dor; E D Williams; J Colon; H A van Gilse; M Mayer; R J Sylvester; M van Glabbeke
Journal:  Eur J Cancer       Date:  1979-08       Impact factor: 9.162

3.  Papillary thyroid carcinoma: the impact of therapy in 576 patients.

Authors:  E L Mazzaferri; R L Young; J E Oertel; W T Kemmerer; C P Page
Journal:  Medicine (Baltimore)       Date:  1977-05       Impact factor: 1.889

Review 4.  Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement.

Authors:  F Pacini; F Lippi
Journal:  J Endocrinol Invest       Date:  1999       Impact factor: 4.256

5.  Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy.

Authors:  J R Gill; M Reyes-Múgica; S Iyengar; K K Kidd; R J Touloukian; C Smith; M S Keller; M Genel
Journal:  J Pediatr       Date:  1996-09       Impact factor: 4.406

6.  Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period.

Authors:  I D Hay; C S Grant; J A van Heerden; J R Goellner; J R Ebersold; E J Bergstralh
Journal:  Surgery       Date:  1992-12       Impact factor: 3.982

7.  Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer.

Authors:  G F Scheumann; O Gimm; G Wegener; H Hundeshagen; H Dralle
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

8.  Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).

Authors:  J Farahati; C Reiners; M Stuschke; S P Müller; G Stüben; W Sauerwein; H Sack
Journal:  Cancer       Date:  1996-01-01       Impact factor: 6.860

Review 9.  Management of the thyroid nodule.

Authors:  J P Campbell; H C Pillsbury
Journal:  Head Neck       Date:  1989 Sep-Oct       Impact factor: 3.147

Review 10.  Postoperative management of differentiated thyroid cancer.

Authors:  Erik G Cohen; R Michael Tuttle; Dennis H Kraus
Journal:  Otolaryngol Clin North Am       Date:  2003-02       Impact factor: 3.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.